Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 818-829

  Loeffler, M ^a   Brosteanu, O ^a   Hasenclever, D ^a   Sextro, M ^a   Assouline, D ^a   Bartolucci, A A ^a   Cassileth, P A ^a   Crowther, D ^a   Diehl, V ^a   Fisher, R I ^a   Hoppe, R T ^a   Jacobs, P ^a   Pater, J L ^a   Pavlovsky, S ^a   Thompson, E ^a   Wiernik, P ^a  

^a Institute for Medical Informatics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0031887688     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.818     Document Type: Article

References (58)

1. DeVita VT, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:891-895, 1970
2. Bonnadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine and imidazole carboximide versus MOPP. Cancer 36:252-259, 1975
3. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
4. Connors JM, Klimo P, Adams G, et al: MOPP/ABV hybrid versus alternating MOPP/ABVD for advanced Hodgkin's disease. Proc Am Soc Clin Oncol 11:317, 1992 (abstr)
5. Viviani S, Bonnadonna G, Santoro A, et al: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 14:1421-1430, 1996
6. Bartlett NL, Rosenberg SA, Hope RT, et al: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 13:1080-1088, 1995
7. Hasenclever D, Loeffler M, Diehl V: Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. Ann Oncol 7:95-98, 1996 (suppl 4)
8. Diehl V, Sieber M, Rüffer U, et al: BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 8:1-6, 1997
9. Bonnadonna G: Modern treatment of malignant lymphomas: A multidisciplinary approach? Ann Oncol 5:5-16, 1994 (suppl 2)
10. Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
11. Gaynor ER, Fisher RI: Chemotherapy and combined modality treatment in Hodgkin's disease. Curr Opin Oncol 3:822-829, 1991
12. Longo DL, Banks PM, Hoppe RT: Hodgkin's disease. Rev Invest Clin 4:73-83, 1994 (suppl)
13. Meerwaldt JH, Coleman CN, Fisher RI, et al: Role of additional radiotherapy in advanced stages of Hodgkin's disease. Ann Oncol 3:83-85, 1992 (suppl 4)
14. Rosenberg SA: Modern combined modality management of Hodgkin's disease. Curr Opin Oncol 6:470-472, 1994
15. Prosnitz LR, Roberts KB: Combined chemotherapy and radiotherapy for Hodgkin's disease. Oncology 6:113-128, 1992
16. Prosnitz LR, Farber LR, Kapp DS, et al: Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol 6:603-612, 1988
17. Longo DL: The case against routine use of radiation therapy in advanced-stage Hodgkin's disease. Cancer Invest 14:353-360, 1996
18. Prosnitz LR, Wu JJ, Yahalom J: The case for adjuvant radiation therapy in advanced Hodgkin's disease. Cancer Invest 14:361-370, 1996
19. Somers R, Henry-Amar M, Meerwaldt JK, et al (eds): Treatment Strategy in Hodgkin's Disease. London, United Kingdom, Libbey, 1990
20. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al: Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: A prematurely terminated British National Lymphoma Investigation randomized trial. Ann Oncol 5:117-120, 1994 (suppl 2)
21. Weiner MA, Leventhal B, Brecher ML, et al: Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 15:2769-2779, 1997
22. Gomez GA, Steinbrenner LS, Han T, et al: Stage IIIA Hodgkin's disease. Results of treatment at 15 years. Proc Am Soc Clin Oncol 7:236, 1988 (abstr 912)
23. Bloomfield CD, Pajak TF, Glicksman AS, et al: Chemotherapy and combined modality therapy for Hodgkin's disease: A progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep 66:835-846, 1982
24. Anderson JR, Stutzman L, Propert K, et al: Combination chemoterapy and radiotherapy for stage IIIA Hodgkin's disease. Blood 64:178a, 1984 (suppl 1, abstr 621)
25. Brizel DM, Winer EP, Prosnitz LR, et al: Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys 19:535-542, 1990
26. Crowther D, Wagstaff J, Deakin D, et al: A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease. J Clin Oncol 2:892-897, 1984
27. Pavlovsky S, Santarelli MT, Sackmann Muriel F, et al: Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A&B Hodgkin's disease. Ann Oncol 3:533-537, 1992
28. Pavlovsky S, Mascio M, Santarelli MT, et al: Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I + II Hodgkin's disease. J Natl Cancer Inst 80:1466-1473, 1988
29. Fabian CJ, Mansfield CM, Dahlberg S, et al: Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. Ann Intern Med 120:903-912, 1994
30. Glick JH, Tsiatis AA: MOPP/ABVD chemotherapy for advanced Hodgkin's disease. Ann Intern Med 104:876-878, 1986
31. Glick J, Tsiatis A, Chen M: Improved survival with MOPP-ABVD compared to BCVPP ± radiotherapy for advanced Hodgkin's disease: 6-year ECOG results. Blood 76:351a, 1990 (suppl 1, abstr)
32. Rosenberg SA, Kaplan HS: The evolution and summary results of the Stanford clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 11:5-22, 1985
33. O'Dwyer PJ, Wiernik PH, Finlay R, et al: A randomized trial of radiotherapy and MOPP vs MOPP alone for stages IB-IIIA Hodgkin's disease. Proc Am Soc Clin Oncol 2:214, 1983 (abstr C-838)
34. Yelle L, Bergsagel D, Basco V, et al: Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trial Group multicenter clinical trial. J Clin Oncol 9:1983-1993, 1991
35. Glick JH, Barnes JM, Bakemeier RF, et al: Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology Group. Cancer Treat Rep 56:855-870, 1982
36. Glick J, Tsiatis A, Prosnitz L, et al: Improved survival with sequential BleoMOPP followed by ABVD for advanced Hodgkin's disease. Blood 70: 245a, 1987 (suppl 1, abstr 836)
37. Diehl V, Loeffler M, Pfreundschuh M, et al: Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. Ann Oncol 6:901-910, 1995
38. Jones SE, Coltman CA, Grozea PN, et al: Conclusions from clinical trials of the Southwest Oncology Group. Cancer Treat Rep 66:847-853, 1982
39. Grozea PN, DePersio EJ, Coltman CA, et al: Chemotherapy alone vs. combined modality treatment for stage III Hodgkin's disease: a five-year follow-up of Southwest Oncology Group study #7518. Proc Am Soc Clin Oncol 4:201, 1985 (abstr C-783)
40. Assouline D, Adeleine P, Jaubert J, et al: Advanced stages Hodgkin's disease: Long term results of the LMS 80 protocol. Proc Am Soc Clin Oncol 12:381, 1993 (abstr 1299).
41. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
42. Mauch PM, Kalish LA, Marcus KC, et al: Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood 87:3625-3632, 1996
43. Henry-Amar M, Aeppli DM, Anderson J, et al: Workshop statistical report, in Somers R, Henry-Amar M, Meerwaldt JK, et al (eds): Treatment Strategy in Hodgkin's Disease. London, United Kingdom, Libbey, 1990, pp 169-418
44. Hasenclever D, Diehl V: A numerical index to predict tumor control in advanced Hodgkin's disease. Blood 88:673a, 1996 (suppl 1, abstr 2680)
45. Ferme C, Berger F, Gabarre J, et al: A randomized trial of chemotherapy 6 cycles plus high-dose radiotherapy versus chemotherapy alone 8 cycles in stage IIIB-IV Hodgkin's disease. Proc Am Soc Clin Oncol 14:394, 1995 (abstr 1236)
46. Boivin JF, Hutchinson GB, Zauber AG, et al: Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 87:732-741, 1995
47. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12:312-325, 1994
48. van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW, et al: Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063-1073, 1994
49. Valagussa P, Bonnadonna G: Hodgkin's disease and second malignancies. Ann Oncol 4:94-95, 1993
50. Lacher MJ, Redman JR (eds): Hodgkin's Disease: The Consequences of Survival. Philadelphia, PA, Lea & Febiger, 1990
51. Henry-Amar M: Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's Disease. Ann Oncol 3:117-128, 1992 (suppl 4)
52. Henry-Amar H, Joly F: Late complications after Hodgkin's disease. Ann Oncol 7:115-126, 1996 (suppl 4)
53. Pepe MS, Mon M: Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12:737-751, 1993
54. Stewart LA, Parmar MK: Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 341:418-422, 1993
55. Olkin I: Statistical and theoretical considerations in meta-analysis. J Clin Epidemiol 48:133-146, 1995
56. Bailar JC III: The promise and problems of meta-analysis. N Engl J Med 337:559-561, 1997
57. LeLorier J, Gregoire G, Benhaddad A, et al: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 337:536-542, 1997
58. Peto R: Why do we need systematic overviews of randomized trials? Stat Med 6:233-244, 1987